Treatment of hepatitis B virus-associated membranous nephritis patients in Chinese: an open parallel controlled trial

2011 ◽  
Vol 49 (6) ◽  
Author(s):  
Gaosi Xu ◽  
Zhibing Duang ◽  
Xiaopeng Wu ◽  
Hongchang Zou ◽  
Xiangdong Fang ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Controlled Trial ◽  
B Virus ◽  
Membranous Nephritis ◽  
Open Parallel

Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice

1997 ◽  
Vol 26 (1) ◽  
pp. 131-137 ◽  
Author(s):  
S.M. Fazle Akbar ◽  
Kazunori Kajino ◽  
Kenji Tanimoto ◽  
Kiyotaka Kurose ◽  
Toshikazu Masumoto ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Transgenic Mice ◽  
Surface Antigen ◽  
Controlled Trial ◽  
Virus Surface ◽  
Virus Surface Antigen ◽  
B Virus

Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B

2013 ◽  
Vol 31 (22) ◽  
pp. 2765-2772 ◽  
Author(s):  
Yi-Hsiang Huang ◽  
Liang-Tsai Hsiao ◽  
Ying-Chung Hong ◽  
Tzeon-Jye Chiou ◽  
Yuan-Bin Yu ◽  
...  
Keyword(s):  
Viral Load ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Controlled Trial ◽  
Control Group ◽  
Hbv Reactivation ◽  
Antiviral Prophylaxis ◽  
B Virus ◽  
To Receive

Purpose The role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation before rituximab-based chemotherapy in patients with lymphoma and resolved hepatitis B is unclear. Patients and Methods Eighty patients with CD20+ lymphoma and resolved hepatitis B were randomly assigned to receive either prophylactic entecavir (ETV) before chemotherapy to 3 months after completing chemotherapy (ETV prophylactic group, n = 41) or to receive therapeutic ETV at the time of HBV reactivation and hepatitis B surface antigen (HBsAg) reverse seroconversion since chemotherapy (control group, n = 39). Results Fifty-eight patients (72.5%) were positive for hepatitis B surface antibody, and HBV DNA was undetectable in 50 patients (62.5%). During a mean 18-month follow-up period, one patient (2.4%) in the ETV prophylactic group and seven patients (17.9%) in the control group developed HBV reactivation (P = .027). The cumulative HBV reactivation rates at months 6, 12, and 18 after chemotherapy were 8%, 11.2%, and 25.9%, respectively, in the control group, and 0%, 0%, and 4.3% in the ETV prophylactic group (P = .019). Four patients (50%) in the control group had HBsAg reverse seroconversion after HBV reactivation. The cumulative HBsAg reverse seroconversion rates at months 6, 12, and 18 since chemotherapy were 0%, 6.4%, and 16.3% in the control group, respectively, which were significantly higher than those in the ETV prophylactic group (P = .032). Patients with detectable or undetectable viral load could develop HBV reactivation and HBsAg reverse seroconversion. Conclusion Undetectable HBV viral load before chemotherapy did not confer reactivation-free status. Antiviral prophylaxis can potentially prevent rituximab-associated HBV reactivation in patients with lymphoma and resolved hepatitis B.

Thymosin alpha 1 for patients with hepatitis B virus-related acute-on-chronic liver falure: a randomized controlled trial

2020 ◽  
Vol 73 ◽  
pp. S498-S499
Author(s):  
Jun-Feng Chen ◽  
Shu-Ru Chen ◽  
Zi-ying Lei ◽  
Hui-Juan Cao ◽  
Shao-Quan Zhang ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Controlled Trial ◽  
Chronic Liver ◽  
Randomized Controlled ◽  
B Virus ◽  
Thymosin Alpha 1

A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis

1994 ◽  
Vol 21 (5) ◽  
pp. 872-877 ◽  
Author(s):  
Yuan-Jen Wang ◽  
Shou-Dong Lee ◽  
Mao-Chih Hsieh ◽  
Han-Chieh Lin ◽  
Fa-Yauh Lee ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Controlled Trial ◽  
Double Blind ◽  
Randomized Controlled ◽  
B Virus ◽  
Postnecrotic Cirrhosis
Sign in / Sign up

Export Citation Format

Share Document